Mer­ck­'s Roger Perl­mut­ter pays $300M to scoop up a bat­tered Im­mune De­sign for its I/O work

Just months af­ter Im­mune De­sign trig­gered an ex­o­dus of in­vestors with news of a Phase II set­back on its lead­ing im­muno-on­col­o­gy work, Mer­ck has stepped up to buy the com­pa­ny and plug it in­to its im­munol­o­gy group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER